HIV-1 vaccine - Sumagen

Drug Profile

HIV-1 vaccine - Sumagen

Alternative Names: Killed-whole HIV-1 vaccine; SAV-001; SAV-001H

Latest Information Update: 05 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Western Ontario
  • Developer Sumagen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 03 Sep 2013 HIV-1 vaccine - Sumagen is available for licensing as of 03 Sep 2013. http://www.sumagen.co.kr/english/
  • 03 Sep 2013 Immunogenicity & adverse events data from a phase I trial in HIV-1 infections released by Sumagen
  • 01 Sep 2013 Sumagen completes a phase I trial in HIV-1 infections in USA (NCT01546818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top